CompletedPHASE2, PHASE3NCT00328653

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)

Studying Vernal keratoconjunctivitis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Santen SAS
Principal Investigator: David BenEzra, Pf
Haddassah University Hospital
Intervention: Cyclosporine NOVA22007 0.05%(drug)
Enrollment: 118 target
Eligibility: 4 years · All sexes
Timeline: 2006

Study locations (1)

Groupe Hospitalier Bichat-Claude Bernard, Paris, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00328653 on ClinicalTrials.gov

Other trials for Vernal keratoconjunctivitis

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGNCT06913790
Evaluation of Central Corneal Thickness in Patients With Vernal Keratoconjunctivitis Using Topical Steroids
Superior University

See all trials for Vernal keratoconjunctivitis →

← Back to all trials